The End of the ‘One-Size-Fits-All’ Parkinson’s Diagnosis: Why 2026 Is the Year Neurology Goes High-Resolution

Contributed Commentary by Dr. Sonya Dumanis, COO, Coalition for Aligning Science 

August 14, 2026 | For over 200 years, neurology has relied on James Parkinson’s 1817 clinical observations as the definitive anchor for understanding Parkinson’s disease. Resting tremor, stooped posture, and a shuffling gait have long served as the standard diagnostic triad. Yet, Parkinson’s is far from a monolithic motor disease. It presents with a dizzying variation in symptoms, age of onset, and rate of progression, deeply impacting sleep, cognitive performance, and mood. 

Despite this heterogeneity, our diagnostic and treatment frameworks remain largely shackled to outward, macro-level symptoms. Traditional therapies focus heavily on catch-all symptom management rather than isolating individual disease roots. To pause, halt, or reverse Parkinson’s, we must pivot toward a precision medicine approach. This requires mapping the disease as a complex, heterogeneous system and treating the unique biological causes of an individual’s condition rather than chasing external downstream effects. 2026 marks the definitive inflection point where this high-resolution future becomes reality. 

Deconstructing the "Molecular Soup" 

Parkinson’s does not exist in a vacuum; it is part of a broader spectrum of neurodegenerative conditions. It sits alongside atypical variations like Progressive Supranuclear Palsy, Corticobasal Degeneration, and Multiple System Atrophy. Layered on top is a complex "molecular soup" of interacting proteins, where alpha-synuclein frequently co-mingles with proteins traditionally associated with Alzheimer's disease, such as tau and amyloid-beta. Crucially, this pathological protein aggregation appears to trigger and accelerate neuroinflammation, creating a sustained chronic immune response in the brain.  

This cross-pathology insight introduces a steep clinical challenge. If a patient’s disease progression is primarily driven by tau or runaway neuroinflammation, a therapy designed to target alpha-synuclein will likely be ineffective. Instead of assuming a uniform pathology, the field must map the exact biological landscape of the living brain, analyzing the interplay between multiple disease-linked proteins to create an individualized blueprint of progression. 

On the Cusp of Clarity: Hope for an Alpha-Synuclein PET Breakthrough  

Historically, a steep hurdle in Parkinson's research has been the inability to see alpha-synuclein in a living patient. Unlike Alzheimer’s disease, which was revolutionized by amyloid and tau PET imaging, confirming alpha-synuclein aggregates traditionally required post-mortem tissue analysis. That barrier seems to be finally falling. The field is experiencing its own "imaging moment" with the rapid advancement of alpha-synuclein (aSYN) PET tracers entering first-in-human studies.  

Recent clinical milestones, including first-in-human data from novel tracers presented at the March 2026 International Conference on Alzheimer’s and Parkinson’s Diseases from AC Immune, Merck, and Modag, are demonstrating that we may be able to now capture alpha-synuclein deposits in the living brain. These tracers are showing selective binding to alpha-synuclein aggregates over other misfolded proteins, offering a direct window into the pathology in the brain. Building on this moment, a few months later, MJFF convened over 100 individuals working in this area to discuss progress to date and next steps.

The implications for clinical trial design could be transformative. Instead of waiting years to observe changes in clinical scales, developers can use aSYN PET imaging as a real-time biomarker to confirm target engagement, stratify patients based on actual alpha-synuclein burden, and determine rapidly whether an investigational therapy is successfully clearing pathological aggregates. 

Targeting the Cellular Engine: LRRK2 Trials 

As our imaging resolution sharpens, so does our therapeutic targeting. The era of relying solely on levodopa—a 1960s-era masterwork that manages motor symptoms by replacing lost dopamine but leaves the underlying neurodegenerative fire burning—is yielding to genetic and pathway-specific interventions. 

A prime example of this paradigm shift is the targeting of the Leucine-Rich Repeat Kinase 2 (LRRK2) pathway, where hyperactivity impairs cellular recycling and lysosomal function, driving toxic protein accumulation. The frontline effort to validate this pathway was the Phase 2b LUMA trial by Biogen and Denali Therapeutics, evaluating their LRRK2 inhibitor, BIIB122. 

Topline results reported in May 2026 revealed the study did not meet its primary or secondary endpoints, leading to the discontinuation of BIIB122 for idiopathic Parkinson’s. However, clinical efficacy was likely obscured by evaluating a drug designed for a specific biological problem within a broad patient population where LRRK2 dysfunction was not the primary driver of neurodegeneration. These findings underscore how a pathway-specific therapy may require a pathway-specific patient population.  

Following the LUMA readout, Denali Therapeutics is independently advancing its Phase 2a BEACON study, narrowing its scope exclusively to a molecularly stratified cohort of individuals harboring a pathogenic LRRK2 variant. Meanwhile, the broader LRRK2 hypothesis remains incredibly vibrant. Arvinas successfully completed a Phase 1 trial for ARV-102, a novel approach focused on degrading the LRRK2 protein, and Neuron23 is advancing its Neulark trial (NEU-411), which exclusively enrolls individuals showing explicit biomarker evidence of elevated LRRK2 activity. The pivot away from catch-all trials toward molecularly stratified cohorts may be the key that will finally unlock the cellular engine of Parkinson's disease. 

Ecosystems of Discovery: Building the Dataset 

Scaling this high-resolution approach requires an unprecedented level of open-science collaboration to build comprehensive biological datasets. Across the US and Europe, massive parallel efforts are building infrastructure to harmonize clinical cohorts and anchor them directly into the global data network. 

Backed by Europe's Innovative Health Initiative (IHI), the European Platform for Neurodegenerative Diseases (EPND) is a major public-private partnership actively dismantling data silos across the continent and providing a platform for biomarker discovery and dataset standardization across European nations. Integrating more than 80 cohorts representing over 240,000 research participants, EPND offers a secure platform for European biomarker discovery, standardizing clinical and biosample datasets across a dozen European nations. 

By supporting key programs like Collaborative Research Network (CRN), Global Parkinson’s Genetics Program (GP2) and Parkinson’s Precision Medicines Initiative (PPMI), Aligning Science Across Parkinson’s (ASAP) is driving international team science forward. These programs collaborate to tackle high-priority research questions while building essential foundational resources, ranging from genetics and multi-omics to deep natural history studies.